Navigation Links
PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
Date:12/1/2009

identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 as filed with the SEC on November 6, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this re
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
2. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
3. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
4. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
5. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
6. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
7. PAREXEL Expands Global Clinical Pharmacology Capabilities
8. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
9. Malaria Experts Call on Federal Government to Increase Support for Research and Development
10. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
11. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... 22, 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... Day and Panera (Nasdaq: PNRA - Free Report ) as ... analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), ... SHPG - Free Report ). Here is a ... the Day : The biotech bull market is ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... Medical Imaging (RMI) in Flint announced today that it is ... Breast Magnetic Resonance Imaging (MRI) by the American College of ... the Breast MRI Accreditation Program to recognize imaging ... for Breast MRI. RMI received this new distinction after a ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... trial program for APD597 (JNJ-38431055) under its collaboration with ... APD597 and has notified Arena that it is terminating ... GPR119 agonist intended for the treatment of type 2 ...
Cached Medicine Technology:Exciting Healthcare News for Women of Mid Michigan 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 3Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 4Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 5
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Mi40x , the latest guide from ... people how they can use a simple 4-minute trick to ... of weeks has caught the attention of Shane Michaels, prompting ... the most well-known bodybuilders in the industry, and if he ... that in itself is a testament to how effective this ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Mueller Sports ... Plantar Fasciitis, an exciting new product that provides non-drug ... to stay active while you heal. The package includes ... truly a new technology – it is not kinesiology ... FasciaDerm® PFTape™ System for Plantar Fasciitis is ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... leading cause of infections in hospitals can be dramatically reduced, ... The program, cheap and easy to implement, is sparking intrigue ... , HPMC is the first acute care facility to successfully ... urine, currently under increased scrutiny for causing deadly infections in ...
... ,missiles, to hurl at visitors for his own amusement, report ... Santino, a male chimp at the Furuvik Zoo in Lund, ... the zoo opened collecting rocks and other "ammunition" to hurl ... around mid-morning. , He stored the items at various sites ...
... to Provide Information on Medicare Advantage Special Needs ... ROCK, Ark., March 9 A series of ... with chronic illness maintain a healthy lifestyle and ... for their unique needs will be offered during ...
... National Commander of the Disabled American Veterans begins a ... for budget reform legislation to ensure sufficient, timely and ... urging them to reject a contentious proposal that would ... from the government,s side of the ledger to insurance ...
... in the international journal Chest , by Neil ... disease (COPD) who breathed a mix of 60% helium ... to exercise longer and harder than those who breathed ... significant because research has shown that patients who perform ...
... announced in 2004 an initiative to have the health records of all ... this daunting task. However, unfortunately, unsatisfactory progress has been made to ... goal will likely be met by the 2014 deadline previously announced. ... ...
Cached Medicine News:Health News:Hollywood Hospital's Trend-Setting Program to Drastically Cut Infections 2Health News:Thinking Man's Chimp Shows 1st Animal 'Planning' 2Health News:Thinking Man's Chimp Shows 1st Animal 'Planning' 3Health News:Free Seminars Offered to Arkansas Seniors with Diabetes and Other Chronic Illnesses 2Health News:Disabled Veterans Leader Presses Issues with Key Lawmakers 2Health News:Helium helps lung patients breathe easier 2Health News:EMRConsultant.com Supports the American Recovery and Reinvestment Act of 2009 2
Reusable shielded cable...
... The STREP A OIA MAX test ... of Group A Strep with a simple, ... minutes. This combination of performance, speed, and ... care while reducing overall costs for diagnosing ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... a high performance assay for the undifferentiated ... with a simple, easy-to-use test that provides ... Assay advantages include superior performance with mucoid ... 14-day viral culture enables you to decrease ...
Medicine Products: